## Edgar Filing: Dasu Badri N - Form 4

Dasu Badri N Form 4							
October 20, 2017							
	FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549					287	
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. <i>See</i> Instruction 1(b).	Filed pursuant to S Section 17(a) of the 1	F CHANGES IN E SECURI Section 16(a) of the Public Utility Holdi of the Investment C	Number: January 31, Expires: 2005 Estimated average burden hours per response 0.5				
(Print or Type Respon	ses)						
1. Name and Address of Reporting Person <u>*</u> Dasu Badri N		2. Issuer Name and 7 Symbol ACELRX PHARM INC [ACRX]	-	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
C/O ACELRX	First) (Middle) ICALS, INC., 351 RIVE	3. Date of Earliest Tra (Month/Day/Year) 10/19/2017	nsaction	Director X Officer (give below) Chief Er	title 10% Owner below) ngineering Officer		
(Street) 4. If Amendment, Date Origina Filed(Month/Day/Year)			e Original	<ol> <li>6. Individual or Joint/Group Filing(Check Applicable Line)</li> <li>_X_ Form filed by One Reporting Person</li> </ol>			
REDWOOD CIT	Y, CA 94063			Form filed by M Person	Iore than One Reporting		
(City) (S	State) (Zip)	Table I - Non-De	erivative Securities A	equired, Disposed of	, or Beneficially Owned		
	ransaction Date 2A. Deen nth/Day/Year) Execution any (Month/I	med 3.	4. Securities Acquired n(A) or Disposed of (D) (Instr. 3, 4 and 5) (A) or	<ul> <li>5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)</li> </ul>	6. Ownership 7. Nature 6 Form: Direct Indirect (D) or Beneficial Indirect (I) Ownershij (Instr. 4) (Instr. 4)	l	
Common 10/1 Stock	19/2017	М	37,500 A <sup>\$</sup> 1.2	74,390 <u>(1)</u>	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

## Edgar Filing: Dasu Badri N - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	orDeri Secu Acq or D (D) (Inst	5. Number of 6. Date Exercisable and Derivative Expiration Date Securities (Month/Day/Year) Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		ate	7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8 1 2 ()
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Option (Right to Buy)	\$ 1.2	10/19/2017		М		37,500	(2)	10/25/2017	Common Stock	37,500	
Reporting Owners											

Reporting Owner Name / Address			Relationships		
	Director	10% Owner	Officer	Other	
Dasu Badri N C/O ACELRX PHARMACEUTICALS, INC.					
351 GALVESTON DRIVE REDWOOD CITY, CA 94063		Chief Engineering	Chief Engineering Officer		
Signatures					
/s/Martha Adler					

/s/Martha Adler, Attorney-In-Fact 10/19/2017

\*\*Signature of Reporting Person

Date

## **Explanation of Responses:**

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- (1) Balance includes non-reportable acquisition of 14,360 shares of Common Stock through the Company's Employee Stock Purchase Plan.
- (2) Fully vested.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

8 E S